Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) Sees Significant Decline in Short Interest

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) saw a significant decline in short interest in the month of October. As of October 15th, there was short interest totaling 643,800 shares, a decline of 27.8% from the September 30th total of 891,600 shares. Currently, 0.1% of the company’s shares are short sold. Based on an average daily volume of 330,300 shares, the short-interest ratio is presently 1.9 days. Based on an average daily volume of 330,300 shares, the short-interest ratio is presently 1.9 days. Currently, 0.1% of the company’s shares are short sold.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in FMS. Todd Asset Management LLC bought a new stake in shares of Fresenius Medical Care AG & Co. KGaA during the first quarter worth about $12,009,000. Hennessy Advisors Inc. acquired a new position in Fresenius Medical Care AG & Co. KGaA during the 2nd quarter valued at about $11,479,000. Millennium Management LLC increased its holdings in Fresenius Medical Care AG & Co. KGaA by 50.0% during the 1st quarter. Millennium Management LLC now owns 1,083,602 shares of the company’s stock worth $26,982,000 after purchasing an additional 361,364 shares in the last quarter. Teachers Retirement System of The State of Kentucky purchased a new stake in shares of Fresenius Medical Care AG & Co. KGaA in the first quarter worth approximately $7,420,000. Finally, Raymond James Financial Inc. lifted its holdings in shares of Fresenius Medical Care AG & Co. KGaA by 1,508.1% in the first quarter. Raymond James Financial Inc. now owns 287,751 shares of the company’s stock valued at $7,165,000 after purchasing an additional 269,857 shares in the last quarter. 8.37% of the stock is owned by institutional investors.

Fresenius Medical Care AG & Co. KGaA Stock Down 1.9%

FMS stock traded down $0.51 during trading on Monday, reaching $26.33. 635,396 shares of the stock were exchanged, compared to its average volume of 353,452. The firm’s 50 day moving average is $26.08 and its 200 day moving average is $26.59. The firm has a market cap of $15.45 billion, a P/E ratio of 21.58, a price-to-earnings-growth ratio of 0.64 and a beta of 0.92. The company has a current ratio of 1.44, a quick ratio of 1.08 and a debt-to-equity ratio of 0.44. Fresenius Medical Care AG & Co. KGaA has a twelve month low of $19.86 and a twelve month high of $30.46.

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) last released its quarterly earnings data on Tuesday, August 5th. The company reported $0.52 EPS for the quarter, beating the consensus estimate of $0.50 by $0.02. Fresenius Medical Care AG & Co. KGaA had a return on equity of 6.75% and a net margin of 3.39%.The firm had revenue of $5.54 billion during the quarter, compared to the consensus estimate of $5 billion. As a group, research analysts forecast that Fresenius Medical Care AG & Co. KGaA will post 1.51 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on FMS shares. Bank of America lowered Fresenius Medical Care AG & Co. KGaA from a “neutral” rating to an “underperform” rating in a research report on Wednesday, October 15th. Weiss Ratings raised Fresenius Medical Care AG & Co. KGaA from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Wednesday, October 8th. Zacks Research upgraded Fresenius Medical Care AG & Co. KGaA from a “hold” rating to a “strong-buy” rating in a research report on Monday, October 6th. UBS Group lowered Fresenius Medical Care AG & Co. KGaA from a “sell” rating to an “underperform” rating in a research note on Wednesday, October 15th. Finally, Morgan Stanley restated an “underweight” rating on shares of Fresenius Medical Care AG & Co. KGaA in a research report on Tuesday, August 12th. One equities research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, one has issued a Hold rating and three have issued a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $27.80.

About Fresenius Medical Care AG & Co. KGaA

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.